Literature DB >> 2455950

Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa.

K Hall1, G Lundin, G Póvoa.   

Abstract

The low molecular weight form of insulin-like growth factor binding protein (35 kD IGFBP), determined in serum by radioimmunoassay during non-fasting conditions, was high at birth and declined with increasing age during childhood and adolescence (N = 149). Inverse correlation was found between chronological age and 35 kD IGFBP values (r = -0.61, P less than 0.001) during childhood and adolescence, but no age dependency was found in adult subjects aged 20-66 years (N = 73). The mean and 95% confidence limits of immunoreactive 35 kD IGFBP were 34 micrograms/l and 15-79 micrograms/l, respectively, in healthy adults (N = 73) in whom the blood samples were drawn after a one-night fast. The mean level of the 35 kD IGFBP in patients with acromegaly (19 micrograms/l, N = 23) was decreased by 50% in comparison with healthy adults, whereas a 2-fold elevation of the mean levels was found in both anorexia nervosa patients (70 micrograms/l, N = 13) and adult patients with GH deficiency (69 micrograms/l, N = 22). In patients with anorexia nervosa, the 35 kD IGFBP levels were inversely related to the body mass index (r = -0.65, P less than 0.02).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455950     DOI: 10.1530/acta.0.1180321

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  8 in total

Review 1.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

2.  Effect of glycemic control on growth hormone and IGFBP-1 secretion in patients with type I diabetes mellitus.

Authors:  L R Salgado; M Semer; M Nery; M Knoepfelmacher; A C Lerário; G Póvoa; S Jana; S M Villares; B L Wajchenberg; B Liberman; W Nicolau
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

3.  Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia.

Authors:  W F Blum; M B Ranke; K Kietzmann; B Tönshoff; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

4.  IGFBP-2 - taking the lead in growth, metabolism and cancer.

Authors:  Steven W Yau; Walid J Azar; Matthew A Sabin; George A Werther; Vincenzo C Russo
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

5.  Nutritional insult and recovery in the neonatal rat cerebellum: insulin-like growth factors (IGFs) and their binding proteins (IGFBPs).

Authors:  G E Shambaugh; N Natarajan; M L Davenport; D Oehler; T Unterman
Journal:  Neurochem Res       Date:  1995-04       Impact factor: 3.996

6.  Anorexia nervosa associated with acromegaloid features, onset of acrocyanosis and Raynaud's phenomenon and worsening of chilblains.

Authors:  M H Rustin; J C Foreman; P M Dowd
Journal:  J R Soc Med       Date:  1990-08       Impact factor: 18.000

7.  Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours.

Authors:  J G Reeve; J A Payne; N M Bleehen
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

8.  Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk.

Authors:  E Weiderpass; K Brismar; R Bellocco; H Vainio; R Kaaks
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.